IL2 and neoplasm: Three weeks after tumor cell injection, two doses of PBS, anti-MSLN CAR-like NK cells, or anti-MSLN uCAR-like NK cells (1.0 × 107) were administered intraperitoneally, with rh-IL2 administered every other day.